If the giants are looking at Neuren/Acadia then IMO NEU would look most attractive. After the success of the Trofinitide trial on 8 Dec NEU is proven to have had the best of the 2018 deal with Acadia. Substantial income to be received from N.America via Acadia PLUS the rest of the worlds Trofinitide belongs 100% to Neu.
PLUS the more promising 2591 molecule that NEU is developing for 4 other Neurological conditions is 100% Neu and following the success of Trofinitide would be hard to bet that it will not be successful.
NEU is the source not ACAD.
If the giants are looking at Neuren/Acadia then IMO NEU would...
-
- There are more pages in this discussion • 9,900 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.21 |
Change
0.225(1.13%) |
Mkt cap ! $2.570B | |||
| Open | High | Low | Value | Volume |
| $20.11 | $20.23 | $19.63 | $5.504M | 274.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 64 | $20.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.21 | 298 | 9 |
View Market Depth
| Last trade - 14.42pm 25/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |